logo
Save Up To $600 On Mattresses During The Tempur-Pedic Memorial Day Sale

Save Up To $600 On Mattresses During The Tempur-Pedic Memorial Day Sale

Forbes23-05-2025
For shoppers sifting through the best Memorial Day mattress sales looking to save on a new setup, it's a good time to take advantage of Tempur-Pedic's holiday promotions. During the Tempur-Pedic Memorial Day Sale, you can save up to $600 on the brand's top mattresses, adjustable bed frames and bedding. The Tempur-Pro Adapt, our top pick from the brand, is currently $200 off. And in addition to saving on a mattress, you can also get $300 in free sleep accessories (like pillows and sheets) from the brand with your purchase.
Below, we've rounded up the best discounts from the Tempur-Pedic mattress sale—including other models that have earned top marks from sleep editors and testers. We recommend taking advantage of these deals while they last over the long weekend.
Known for its dense memory foam feel that's pressure-reliving and supportive at the same time, this upgraded model comes with a cooling cover to help relieve hot sleepers. 'The Tempur-Adapt is one of my favorites from the Tempur-Pedic collections,' says sleep and mattress editor McKenzie Dillon in our roundup of the best memory foam mattresses. Plus, it boasts a more competitive price tag than some of the other brand's models. Get $300 of free accessories with your purchase using code FREE300.
Do hot temperatures repeatedly keep you up, kicking your covers off in the middle of the night? Take $300 off the brand's most advanced cooling mattress, plus get $300 in free bedding accessories over during the Memorial Day mattress sale. It's our editors' pick for the best firm cooling mattress for hot sleepers. The temperature regulating bed offers excellent motion isolation, three firmness level options and includes free delivery with a 10-year warranty. Use code 300FREE to get the bundled accessories.
This cooling mattress is the mid-tier model of Tempur-Pedic's cooling line and it comes in medium or medium-hybrid designs. It offers similar cooling technology as the Luxe version, but boasts a shorter profile with less memory foam. The bed is supportive and temperature-regulating—a great option for those who sleep hot. You can take $300 off this mattress now and get a selection of free accessories with code 300FREE.
As the brand's most affordable offering, this bed-in-a-box is available for under $1,500 this Memorial Day weekend. It's available in an all-foam or hybrid construction and accommodates most body types. It has a medium firmness that balances support with pressure relief. This model also arrives via doorstep delivery for fast and convenient shipping. If you're looking to save big on a Tempur-Pedic model, we consider this the best budget Tempur-Pedic option.
Bundle a new mattress with a premium smart adjustable base from Tempur-Pedic for $200 off. The Tempur-Ergo ProSmart Base is AI-powered and delivers sleep tracking insights, anti-snore technology among other cool features. Each side of the mattress can be controlled via remote or app, making it a great option for couples with different sleeping preferences.
Our sleep editors named this the best Tempur-Pedic mattress overall because it comes in three firmness levels and is available in either foam or hybrid variations—making it appealing to a wide variety of sleepers. It has a machine-washable cover and offers impeccable motion isolation and ample support. This sale is a rare opportunity to pick it up for $200 less than the full price.
Enhance your bedding and buy a new set of pillows from Tempur-Pedic during its Memorial Day sale this weekend. The brand is offering a buy-two-and-save deal where you can get more than $100 off pillows when you buy a set. The Tempur-Cloud Breeze is ideal for hot sleepers who are always chasing the cool side of the pillow. The adaptive foam interior also means you'll enjoy contouring support without having to fluff them. It isn't adjustable like some pillows, but the cover does zip off and is safe for machine washing.
Change the feel of your mattress without having to buy a whole new bed. The Tempur-Adapt Topper adds an extra 3 inches of body-contouring foam and is currently 40% off. We named it the best mattress topper overall, because it's supportive, easy to clean and comes with a 10-year warranty.
These sheets have a silky, airy feel and moisture-wicking properties that are ideal for hot sleepers. They're also equipped with corner straps for a secure fit. They're available in a range of classic and cool tones from white to sleepy blue. Buy this set while it's 50% off to help you sleep cooler this summer.
The best Memorial Day mattress sales include savings of up to $600 or more from top-rated brands like Tempur-Pedic, Sleep Number and DreamCloud. Take advantage of deals on everything from mattresses and bed frames to new sheets.
Tempur-Pedic does offer sales during major holidays like Memorial Day and Labor Day, but they don't have regular promotions like other brands do during the year. That's why holidays are the best time to buy a mattress.
The lifespan of a mattress depends on the bed's construction (whether it's all-foam or hybrid) and how well you take care of it. The average all-foam mattress lasts around seven years and a hybrid mattresss should last around 10-12.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Google should 'walk away' from Waymo
Why Google should 'walk away' from Waymo

Yahoo

time9 minutes ago

  • Yahoo

Why Google should 'walk away' from Waymo

Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

Yahoo

time9 minutes ago

  • Yahoo

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

time9 minutes ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store